For foreign pharmaceutical creditors holding claims against Russian counterparties, the recovery landscape in 2026 has acquired a layer of regulatory complexity that sits entirely outside Russian procedural law. OFAC licensing requirements now intersect directly with the mechanics of tracing and enforcing against Russian assets — creating a sequencing problem that courts in Moscow and Novosibirsk are not equipped to resolve. Understanding where the two regulatory regimes meet, and where they diverge, has become a precondition for any credible recovery strategy in this sector.
Until recently, foreign pharmaceutical creditors approaching Russian asset recovery operated along two largely parallel tracks. On the Russian side, they engaged insolvency proceedings, pledge enforcement, or civil execution — procedures governed by Russian legislation and adjudicated in Russian arbitrazh courts. On the US regulatory side, OFAC licensing requirements applied where the creditor itself, or a transaction intermediary, carried US-person exposure. These tracks intersected only occasionally, typically where enforcement involved a USD-denominated payment or a US correspondent bank.
That picture has shifted. The broadening of designated-entity lists, combined with the expanded definition of facilitation under current OFAC guidance, means that a foreign pharmaceutical creditor pursuing Russian asset recovery now faces a materially higher probability that a step in the recovery chain — a collection agent, a correspondent payment channel, or a third-party custodian — triggers a licensing or blocking obligation. The practical consequence is that the creditor may be unable to move recovered funds without a specific OFAC licence, even where Russian courts have fully recognised the claim and ordered enforcement.
For the pharmaceuticals sector specifically, this dynamic is sharpened by two features of the Russian market that are largely absent in other industries. First, pharmaceutical distribution in Russia has operated under an accelerated parallel import regime since 2022. Russian distributors holding inventory of foreign-branded medicines frequently do so through corporate structures that include entities in EAEU jurisdictions — Kazakhstan, Belarus, Armenia — some of which carry exposure to the OFAC designation lists either directly or through beneficial ownership. Second, Roszdravnadzor, the Russian medicines regulator, issues licences that attach to legal entities, not to products. When a licensed distributor enters insolvency, the licence does not transfer to the insolvency estate in the ordinary way — creating a valuation gap that creditors who have not anticipated this feature consistently underestimate.
The combined effect is a before-and-after shift in recovery strategy. Before the current regulatory posture, a creditor could map the Russian asset base, identify recoverable value, and proceed to enforcement relatively linearly. Today, the same creditor must run a parallel OFAC exposure analysis before committing to any enforcement step — because discovering a blocking obligation mid-proceeding can halt recovery entirely and trigger its own compliance exposure.
"
For foreign pharmaceutical creditors assessing their Russian asset recovery options in light of current regulatory conditions, an early-stage mapping exercise — covering both the Russian procedural position and the OFAC exposure profile — is the most effective way to avoid sequencing failures. Make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76
"
The practical impact of this intersection is not uniform across creditor types. Three categories face the most acute exposure.
The first is the foreign trade creditor — typically a European or North American pharmaceutical manufacturer or distributor — holding an unpaid supply contract claim against a Russian counterparty that has entered or is approaching insolvency. These creditors face the sequencing problem most directly. Russian insolvency proceedings move on their own timetable; the creditor's ability to file in the register of creditors, attend creditors' meetings, and participate in asset realisation is governed by Russian procedure. But the point at which recovered value must actually move — typically at the distribution stage — is precisely where the OFAC licensing analysis becomes operative.
The second category is the secured creditor holding a pledge over Russian pharmaceutical assets. This might include inventory, intellectual property licences, or real property occupied by a pharmaceutical manufacturer or distributor. Pledge enforcement in Russia is a discrete procedural pathway, and it does not automatically pass through insolvency. But where the pledged asset is inventory of a product subject to OFAC-related supply chain controls, or where the pledgor entity is itself designated or carries beneficial ownership exposure, the creditor's ability to realise the collateral may be constrained before a Russian court has said anything at all.
The third category — frequently overlooked — is the foreign institutional investor holding debt instruments issued by Russian pharmaceutical companies or backed by Russian pharmaceutical receivables. These creditors often carry indirect OFAC exposure through custodians, trustees, or payment agents who are US persons or operate through US infrastructure. The recovery path for these creditors is particularly complex because the Russian-law enforcement steps and the US-person compliance steps may be in direct procedural conflict.
The EAEU dimension adds a further wrinkle. Several major Russian pharmaceutical distributors operate through holding structures in Kazakhstan or Kyrgyzstan. An asset tracing exercise that follows value across these borders encounters not only Russian civil procedure but also the insolvency and enforcement laws of EAEU member states — each with its own interaction with international sanctions frameworks. A creditor who maps only the Russian entity will miss the asset.
The practical response to this intersection is not to defer enforcement pending regulatory clarity — that clarity is unlikely to arrive on any near-term timeline, and Russian limitation periods do not pause for US regulatory developments. The response is to restructure the recovery strategy so that the OFAC analysis precedes, rather than follows, the Russian enforcement steps.
In concrete terms, this means four things.
First, conduct an OFAC exposure mapping of the full recovery chain before filing any Russian enforcement action. This includes the debtor entity, its known beneficial owners, any EAEU-jurisdiction affiliates, and any payment intermediaries that would need to be used to move recovered funds. Where a US-person exposure exists, identify whether a general licence applies or whether a specific licence application is warranted. This step requires engagement with counsel admitted in the relevant US regulatory context — Vetrov & Partners collaborates with trusted counsel in the relevant jurisdiction for matters involving foreign-law compliance requirements of this nature.
Second, assess the Roszdravnadzor licensing position of the debtor entity early. If the debtor holds pharmaceutical distribution or manufacturing licences, understand how those licences interact with the insolvency regime, whether they form part of the recoverable asset base, and whether any licensing gaps affect asset valuation. This is a Russian-law question that sits within the firm's practice.
Third, where the asset recovery strategy involves EAEU-jurisdiction entities, ensure that the tracing exercise extends to those jurisdictions and that local enforcement options are preserved in parallel with the Russian proceedings. Assets that migrate across the EAEU border before enforcement is initiated are materially harder to recover.
Fourth — and most immediately — review existing contracts with Russian pharmaceutical counterparties for governing-law and enforcement clauses. Where arbitration clauses point to institutional forums, assess whether the institutional rules, or the seat of arbitration, create additional OFAC exposure. This review is time-sensitive: counterparties in financial difficulty may attempt to use procedural complexity as a delaying mechanism, and a creditor who has not mapped its enforcement pathway in advance is vulnerable to that tactic.
Creditors who have not yet conducted an integrated Russian-OFAC recovery assessment for their pharmaceutical sector exposures are operating with an incomplete picture of their options. Make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76
Q: What specifically changed in the regulatory intersection between OFAC and Russian asset recovery in the pharmaceuticals sector? A: The primary shift is in the practical probability that a step in the Russian recovery chain now triggers an OFAC licensing or blocking obligation. The broadening of designated-entity lists and the expanded treatment of facilitation under current OFAC guidance means that collection agents, correspondent payment channels, and custodians involved in a Russian recovery exercise carry a higher likelihood of US-person or designated-entity exposure than they did previously. For pharmaceutical creditors specifically, the parallel import structures used by Russian distributors — often involving EAEU-jurisdiction entities — have increased the number of recovery chain participants that require OFAC screening.
Q: Which foreign creditors holding Russian pharmaceutical assets are most directly affected by this development? A: Three categories face the most direct impact. Foreign trade creditors with unpaid supply contract claims against Russian counterparties in or approaching insolvency must now run an OFAC exposure analysis before committing to enforcement steps that were previously straightforward. Secured creditors holding pledges over pharmaceutical inventory, IP licences, or real property face the risk that the pledged asset itself, or the pledgor's beneficial ownership structure, creates a blocking obstacle before Russian enforcement even begins. Institutional investors holding Russian pharmaceutical debt instruments face potential conflict between the Russian enforcement timetable and the compliance obligations of US-person intermediaries in their custody or payment chains. Creditors operating across EAEU borders — where Russian pharmaceutical distributors frequently hold assets in Kazakhstan or Kyrgyzstan — face additional jurisdictional complexity.
Q: What should a foreign pharmaceutical creditor do now to protect its recovery position? A: The priority is to conduct an integrated OFAC exposure mapping of the full recovery chain — covering the debtor entity, its beneficial owners, EAEU affiliates, and all payment intermediaries — before initiating any Russian enforcement action. Where a US-person exposure is identified, assess whether a general licence covers the intended steps or whether a specific licence application is required. Simultaneously, assess the Roszdravnadzor licensing position of the debtor: pharmaceutical distribution and manufacturing licences do not transfer automatically in Russian insolvency proceedings, which affects asset valuation. Review arbitration and governing-law clauses in existing contracts for additional OFAC exposure. Limitation periods under Russian civil procedure continue to run regardless of regulatory uncertainty, so deferring this assessment carries its own risk.
Vetrov & Partners is a Russian boutique law firm established in 2009, recognised by Pravo-300 for eight consecutive years and listed as a trusted adviser by the German Consulate General in Novosibirsk.
The firm's asset tracing and recovery practice advises foreign creditors — including trade creditors, secured lenders, and institutional investors — on enforcing claims against Russian entities and tracing assets across Russian and EAEU jurisdictions. Where a matter involves foreign-law compliance requirements, including US regulatory exposure, the firm collaborates with trusted counsel in the relevant jurisdiction. With over 1,000 matters handled since inception, the team brings direct partner involvement to every engagement.
Enquiries: info@vetrovpartners.com | WhatsApp / Telegram: +7 (983) 510-38-76 | t.me/vitvetcom
This publication is provided for informational purposes only and does not constitute legal advice under Russian or any other applicable law. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Vetrov & Partners is a Russian-qualified law firm. For matters governed by foreign law or requiring local admission in another jurisdiction, we collaborate with trusted counsel in the relevant jurisdiction. For advice regarding your particular situation, please contact info@vetrovpartners.com.
-- Elizaveta Razina Senior Lawyer, Practice Lead -- IP Enforcement & Asset Protection, Vetrov & Partners vetrovpartners.com/razina/